HYPR Hyperfine, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1833769 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.0%
TTM net income YoY25.6%
TTM EPS YoY44.2%
Revenue 3-yr CAGR25.0%
Net income 3-yr CAGR—
Margins
Gross margin52.6%
Operating margin-167.6%
Net margin-156.4%
FCF margin-146.5%
EBITDA margin-162.0%
Returns
ROE-101.7%
ROA-60.0%
ROIC (approx.)-402.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets45.1%
Debt / equity0.42x
Current ratio5.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.56M | $12.89M |
| Cost of revenue | $6.81M | $7.00M |
| Gross profit | $6.75M | $5.89M |
| R&D expense | $17.45M | $22.50M |
| SG&A expense | $16.25M | $17.49M |
| Operating income | -$37.09M | -$43.22M |
| Pretax income | -$35.57M | -$40.72M |
| Income tax | $0 | $0 |
| Net income | -$35.57M | -$40.72M |
| EBITDA | -$35.99M | -$42.22M |
| EPS (basic) | -0.43 | -0.56 |
| EPS (diluted) | -0.43 | -0.56 |
| Weighted avg. shares (diluted) | 81.80M | 72.41M |
| Balance sheet | ||
| Cash & equivalents | $35.09M | $37.67M |
| Receivables | $5.25M | $5.96M |
| Inventory | $7.09M | $5.83M |
| Current assets | $50.91M | $53.71M |
| PP&E, net | $2.55M | $3.12M |
| Total assets | $55.26M | $58.90M |
| Current liabilities | $11.73M | $8.73M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $14.26M | $9.86M |
| Shareholders' equity | $41.01M | $49.04M |
| Net debt | -$35.09M | — |
| Cash flow statement | ||
| Operating cash flow | -$27.95M | -$38.77M |
| Capital expenditure | $1.19M | $383,000 |
| Free cash flow | -$29.13M | -$39.15M |
| Investing cash flow | -$1.19M | -$383,000 |
| Financing cash flow | $27.50M | $1.02M |
| Depreciation & amortization | $1.09M | $1.01M |
| Stock-based compensation | $2.80M | $4.36M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.